Amedisys Inc (NASDAQ:AMED) – Research analysts at Jefferies Group lifted their Q3 2017 earnings estimates for shares of Amedisys in a note issued to investors on Wednesday, according to Zacks Investment Research. Jefferies Group analyst B. Tanquilut now forecasts that the health services provider will post earnings of $0.55 per share for the quarter, up from their prior estimate of $0.53. Jefferies Group has a “Buy” rating and a $60.00 price objective on the stock. Jefferies Group also issued estimates for Amedisys’ Q4 2017 earnings at $0.58 EPS and FY2017 earnings at $2.22 EPS.
Several other brokerages have also recently weighed in on AMED. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. BidaskClub cut shares of Amedisys from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Benchmark Co. upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $56.00 target price on the stock in a research note on Thursday, November 2nd. Royal Bank of Canada restated a “sector perform” rating and set a $62.00 target price (up previously from $56.00) on shares of Amedisys in a research note on Thursday. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $60.00 target price on shares of Amedisys in a research note on Monday, October 9th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $61.00.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/11/11/amedisys-inc-amed-expected-to-post-q3-2017-earnings-of-0-55-per-share.html.
Shares of Amedisys (AMED) traded down $0.14 during trading hours on Thursday, hitting $56.25. 310,900 shares of the stock traded hands, compared to its average volume of 322,348. Amedisys has a 52-week low of $38.00 and a 52-week high of $65.91. The company has a quick ratio of 1.21, a current ratio of 1.33 and a debt-to-equity ratio of 0.16. The company has a market cap of $1,913.69, a PE ratio of 26.98, a PEG ratio of 1.37 and a beta of 0.68.
Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.54 by $0.02. The business had revenue of $380.20 million for the quarter, compared to analysts’ expectations of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.36 EPS.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Federated Investors Inc. PA grew its holdings in shares of Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after purchasing an additional 44 shares in the last quarter. Riverhead Capital Management LLC grew its holdings in shares of Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock valued at $121,000 after purchasing an additional 831 shares in the last quarter. CIBC Asset Management Inc purchased a new position in shares of Amedisys in the second quarter valued at $230,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Amedisys in the third quarter valued at $205,000. Finally, SG Americas Securities LLC grew its holdings in shares of Amedisys by 48.7% in the second quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock valued at $235,000 after purchasing an additional 1,226 shares in the last quarter. 96.36% of the stock is owned by institutional investors and hedge funds.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.